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Diabetes is a chronic disease which arises when the body is unable to use the insulin it 
produces effectively (type 2), or when enough insulin is not produced by the pancreas 
(type 1). (WHO 2015a) 
This thesis aims to find out how effective a drug and diet therapy is in the treatment of dia-
betes (type 2), as well as how nurses and health workers can assist patients in the 
care/management of diabetes using drug and diet therapy. The purpose of this thesis is to 
identify the differences and / or similarities in the treatment of diabetes (type2) focusing on 
medication therapy (pills, insulin, follow up blood sugar test) and diet therapy (eating habit  
& exercise) comparing Finland and the USA. 
The research questions of this thesis were: 1.What are the difference and / or similarities 
between Finland and USA regarding their drug and diet therapy of diabetes (type2)?.       
2. What are the differences in the outcome in both countries after the treatment of diabetes 
(type 2) using drug and diet therapy? 
The data collection method was literature review. Inclusive and exclusive principles were 
set, keywords selected and MEDLINE, CINAHL and SAGE databases used. 
The data collected were analysed using the inductive content analysis. The chosen mate-
rials were read through several times carefully, findings were gathered and classified to 
identify results. 
The results of this thesis answer the research questions of what are the differences and 
similarities Finland and the USA have in their treatment of type 2 diabetes as well the pos-
sible difference in the outcome of their treatments. The results also show the general 
guidelines necessary for nurses, patient and their caregiver (e.g.family) in the manage-
ment of type 2 diabetes.  
 
Keywords: Diabetes, Diabetes type2, diet therapy, drug therapy. 
  
3 
 
4(55) 
 
Table of contents 
Thesis abstract .................................................................................... 2 
Table of contents ................................................................................. 4 
Tables and figures ............................................................................... 6 
Abbreviations ...................................................................................... 7 
1 INTRODUCTION ............................................................................ 8 
2 PATIENT EDUCATION ................................................................. 10 
3 DIABETES .................................................................................... 12 
3.1 Forms of diabetes ..................................................................................... 12 
3.2 Diabetes type 2 ......................................................................................... 13 
4 DIET THERAPY ............................................................................ 15 
4.1 Carbohydrate ............................................................................................ 15 
4.2 Protein ...................................................................................................... 16 
4.3 Fat….. ....................................................................................................... 16 
4.4 Fibre… .......................................... Virhe. Kirjanmerkkiä ei ole määritetty. 
4.5 Alcohol ...................................................................................................... 17 
5 MEDICATION / DRUG THERAPY FOR TYPE 2 DIABETES ........ 18 
5.1 Oral and anti-diabetics agents .................................................................. 18 
5.1.1 Insulia Secretagodues .................................................................... 19 
5.1.2 Insulin Sensitizers ........................................................................... 20 
5.1.3 Alpha-Glucosidase Inhibitors .......................................................... 21 
5.2 Incretin-Based Therapy ............................................................................. 21 
5.2.1 Glucagon Like Peptides-1 (GLP-1) and GLP-1 Receptor 
Agonist/Inhibitor .............................................................................. 22 
5.2.2 Dipeptidylpeptidase-4 (DPP-4) Inhibitor .......................................... 23 
5.3 Selective Sodium Glucose Co-transporter 2 Inhibitor (SGLT2-i) ............... 24 
5.4 Insulin Therapy ......................................................................................... 25 
6 GOAL AND PURPOSE OF THE THESIS ..................................... 27 
7 THESIS IMPLEMENTATION ........................................................ 28 
7.1 Literature review ....................................................................................... 28 
5(55) 
 
7.2 Data collecting process ............................................................................. 29 
7.2.1 Choosing the topic for review .......................................................... 29 
7.2.2 Inclusion and exclusion criteria ....................................................... 30 
7.2.3 Data search result ........................................................................... 31 
7.3 Content analysis ....................................................................................... 35 
7.3.1 Data analysing process................................................................... 36 
8 RESULTS ..................................................................................... 38 
8.1 General guidelines on the management of type 2 diabetes. ..................... 38 
8.1.1 Diabetes and treatment of type 2 diabetes in Finland ..................... 40 
8.1.2 Diabetes and treatment of type 2 diabetes in USA. ........................ 40 
8.2 Similarities and Differences in the diet therapy between Finland and USA.
 41 
8.2.1 Food and eating principles for type 2 diabetes patient in Finland ... 41 
8.2.2 Food and eating principles for type 2 diabetes in USA ................... 41 
8.2.3 Similarities ...................................................................................... 42 
8.2.4 Differences ...................................................................................... 45 
8.3 Similarities and Differences in the drug therapy between Finland and USA.
 45 
8.3.1 Drug Therapy (antidiabetics) in Finland .......................................... 45 
8.3.2 Drug therapy for type 2 diabetes in USA......................................... 46 
8.3.3 Similarities ...................................................................................... 47 
8.3.4 Differences ...................................................................................... 49 
8.4 Result outcome ......................................................................................... 49 
9 DISCUSSION AND CONCLUSION ............................................... 51 
9.1 Reflectiong on the review and result ......................................................... 51 
9.1.1 Conclusion ...................................................................................... 52 
9.2 Ethical and authenticity issues .................................................................. 52 
BIBLIOGRAPHY ................................................................................ 54 
 
 
  
6(55) 
 
Tables and figures 
Figure 1. The first search results from CINAHL. ................................................... 32 
Figure 2.The second search results from CINAHL. ............................................... 33 
Figure 3.The first search results from SAGE......................................................... 34 
Figure 4. The second search results from SAGE. ................................................. 35 
Figure 5. Example of a daily meal 300-400kcal (Diabetestietoa 2015b) ............... 43 
Figure 6. Glycaemic control algorithm for type 2 diabetes treatment. (Medscape 
2015). .................................................................................................................... 48 
 
Table 1. Differences and similarities between GLP-1 receptor agonist and DPP-4 
inhibitor (Blonde 2011). ......................................................................................... 24 
Table 2 Inclusion and Exclusion criteria used in the data search of the thesis. .... 30 
Table 3. Result sub-category of the thesis. ........................................................... 37 
Table 4. Values for HbA1c and plasma glucose level. WHO and ADA criteria.  
(WHO 2006; ADA 2014). ...................................................................................... 39 
Table 5. Percentage of total energy intake. (Diabeetikon Ruokavaliosuositus 
2008). .................................................................................................................... 43 
  
7(55) 
 
Abbreviations 
ADA  American Diabetes Association 
CVD  Cardiovasculardisorder 
DPP-4  Dipeptidylpeptidase -4 
FPG  Fasting Plasma Glucose 
GLP-1  Glucagon-like peptide-1 
HbA1c  Glycated hemoglobin 
IDF  International Diabetes Federation 
NICE  National Institute for Health and Care Excellence 
USA  The United States of America 
WHO  World Health Organization 
ACCE                             American Association of Clinical Endocrinologists 
 
  
8(55) 
 
1  INTRODUCTION 
Diabetes generally is one of the most common diseases worldwide, but recently 
type 2 diabetes is not only seen in adults anymore, but also in children and ado-
lescents (International Diabetes Federation 2014).  This thesis focuses on the use 
of diet and drug therapy as a treatment of diabetes type 2.  It will give an overview 
of how nurses, parents, caregivers and as well as0 patients contribute in the 
treatment of diabetes.  
The main topic of this thesis is to compare the diet and drug therapy in the treat-
ment of diabetes (type2) in Finland and the United States.  Since diabetes, espe-
cially type 1, is showing more cases every day, authors will briefly mention few 
things people can do in order to prevent diabetes.  
According to WHO (2015a), type 2 diabetes that was previously known as non-
insulin-dependent or adult-onset, diabetes results from the body’s ineffective use 
of insulin.  Though type2 diabetes is characterized by multiple metabolic abnor-
malities, Insulin resistance is the most common feature with patients. Hypergly-
caemia which is also connected to type 2 diabetes, develops only when there is an 
accompanying defect in insulin secretion in relation to the degree of insulin re-
sistance. As the duration of type 2 diabetes lengthens, there is a functional defect 
in the pancreatic beta-cell resulting from a decrease in beta cell mass. The pan-
creatic beta cell function defects include decreased production of endogenous in-
sulin, reduced unresponsiveness to glucose and worsening hyperglycaemia. This 
defect basically leads to a need for exogenous insulin (Pratley 2008, 7). 
Type 2 diabetes comprises 90% of people with diabetes around the world and ap-
pears largely as a result of excess body weight and physical inactivity. The com-
mon symptoms include excessive excretion of urine (polyuria), thirst (polydipsia) 
and excess body weight. This symptom is usually less marked. As a result, the 
disease may be diagnosed several years after onset, once complications have 
already arisen. (WHO 2015a). 
This thesis was written using literature review method. After collecting the neces-
sary data and analysing them, the result showed that both Finland and the USA 
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have very similar diet and drug therapy for diabetes type 2 and diabetes treatment 
in general. 
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2 PATIENT EDUCATION  
It is stated by Mellor (2012) that patient education has been a key component of 
diabetes management in Europe for over 30 years. The commonly used model is 
the therapeutic patient education (TPE) (Mühlhauser et al, 1983 as referred to by 
Mellor 2012). The International Diabetes Federation (2005 as stated by Mellor 
2012.) suggests that education should be offered at diagnosis and then frequently 
reviewed at changes of treatment. Dietary advice is important in improving man-
agement of diabetes at diagnosis. Health care department and diabetes UK states 
that the principles of well-framed education are evidence based and fulfil the 
needs of individuals, a structured curriculum, delivered by a competent instructor, 
are quality assured and regularly edited.   
Blood pressure recommendation target for type 2 diabetes is <140/80mmHg. 
However, for people with other medical complication such as kidney damage or 
cerebrovascular damage, the target is <130/80mmHg. It is important for health 
care providers to educate patient about this. Patients can also be taught how to 
measure their own blood pressure and the measures to take when the result is 
below or above normal.  (Bannister 2008.) 
Self-blood glucose monitoring is important for all diabetic patients including the 
newly diagnosed patients. An average quality randomized control trials has also 
proven this. Most of the patients do want to and are able to monitor their own glu-
cose level. The reason for the self-blood glucose monitoring must be authorized 
and patient must be educated on how to interpret the result and the action that 
needs to be carried out whether the blood sugar has raised more or its getting bet-
ter. Health provider must make sure that patient doing the self-blood glucose 
monitoring are reviewed on impact regularly. (Bannister 2008) 
Nursing intervention on diet and nutrition helps patient to be aware of importance 
of healthy eating in relation to diabetes. Individual should take three regular meals 
and ensure different ranges; snacks may be needed between meals and before 
bed where medication/insulin controls diabetes. Patient should take high fibre car-
bohydrates. Always eat more fruit, vegetables as part of meal. Fruit juice must be 
limited because it increases blood sugar quickly. Beans help in control of blood 
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sugars / blood fats. Reduce fat from meat and dairy products. Avoid saturated fats; 
grill, steam and oven-bake foods. Limit the amount of salt in food. Drink about 8 
glasses a day especially water, patient must not add sugar or sweeteners to drinks 
and choose sugar-free drinks. (De Kleijn 2008.) 
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3 DIABETES 
Diabetes is a chronic disease which happens when adequate insulin, a hormone 
that regulates blood sugar, is not produced by the pancreas, or when the insulin 
production cannot be used by the body effectively. This situation leads to hyper-
glycaemia, which is an increase in blood glucose concentrations. The major con-
sequences diabetes has on the body are severe damage to the kidneys, heart 
(e.g. Stroke), eyes, nerves and blood vessels. Statistics show that it is the major 
cause of blindness, amputation and kidney failure. Furthermore, about 347 million 
people in the world have diabetes and in 2012, diabetes was the major cause of 
1.5 million people’s death. The total death amount that would be caused by diabe-
tes in the next ten years is estimated to rise more than 50%, hence it is predicted 
to be the 7th leading cause of death in the world by the year 2030 (WHO 2015a). 
3.1 Forms of diabetes 
Generally, diabetes is categorized into three major forms known as diabetes type 
1, diabetes type 2 and gestational diabetes. 
Diabetes Type 1 is not preventable with current knowledge and was previously 
referred to as insulin dependent, juvenile or childhood- onset diabetes. The cause 
of diabetes type 1 is still not known.  However, the risk for developing type 1 dia-
betes has been linked to exposure to some viral infections or environmental fac-
tors. Also the risk for developing the disease slightly increases, if there is a family 
member with the disease (IDF 2014). Diabetes type 1 is identified by the lack of 
insulin production by the pancreas and requires daily administration of insulin. 
Symptoms of type 1 diabetes include polyuria (excessive urine), polydipsia (ex-
cessive thirst), weight loss, changes in vision, tiredness and constant hunger. 
(WHO, 2015a.)  
Diabetes Type 2, also known as non-insulin dependent or adult-onset diabetes, 
occurs as a result of the body’s ineffective insulin usage.  The common causes of 
diabetes type 2 are unhealthy diet, lack of physical activity and obesity (over 
weight). Its symptoms are similar to that of diabetes type 1, except that they are 
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less obvious, which makes it mostly difficult to be diagnosed in the early stages, 
hence complications would have already risen. (WHO, 2015a.)  
Gestational Diabetes occurs to women during pregnancy. It is indicated by hyper-
glycemia with above normal blood glucose levels but below the diagnostic of dia-
betes. When this happens, the risk of complications during pregnancy and at de-
livery is increased. Also the possibility of having diabetes type 2 in the future is 
higher. Gestational diabetes is determined through prenatal screening, instead of 
reported symptoms. (WHO, 2015a.) 
The authors of this thesis decided to focus on type 2 diabetes because it is be-
coming an increasingly common disease among all ages in the world which, if not 
managed properly, leads to micro and macro vascular complications. These com-
plications can minimize the quality of life and increase morbidity and mortality rate 
(WHO 2015a). The authors wanted to discuss the causes, symptoms, diagnostic 
criteria as well as diet and treatment of type 2 diabetes. 
3.2 Diabetes type 2 
Diabetes type 2, which used to be only seen in adults but can now be diagnosed 
at any age, even with children, because it may remain undetected for many years. 
It is not always, but usually it is associated with obese or overweight people with a 
sedentary life style. Other risk factors that could lead to the development of diabe-
tes type 2 include: family history and history of gestational diabetes. It is often di-
agnosed when complications (e.g. kidney failure, blindness, lower limb amputa-
tion, cardiovascular disease) appear, or when a routine blood or urine glucose test 
is done. During the early stages, diabetes type 2 can be managed through healthy 
diet and regular physical activity but as it progresses, there will be a need for oral 
drug or insulin. (IDF 2014.)  
Management and treatment of type 2 diabetes require monitoring the blood glu-
cose level, which can be done by a care giver or the patients themselves, thus 
self-monitoring of blood glucose. This helps care givers and the patient to access 
and follow the efficiency of their glycemic control plan. Diabetes screening should 
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be done for: overweight children starting at the age of 10 and repeated every 2 
years, adults with body mass index (BMI) of 25 and above, every adult aged 
45years and above,  repeating it every other 3 years, or any young person having 
the risk factor for developing type 2 diabetes. Every three months, examinations of 
blood pressure, eyes as well as skin and bones on feet and legs are done in order 
to prevent diabetes related complications. (Medlineplus 2014.) 
Glycemic control / blood glucose monitoring can be grouped into two categories: 
Patient self-control of blood glucose: For insulin pump therapy and different insulin 
injection SCBG need to be done not less than three times per day. It allows patient 
to determine if they have reached the glycemic target by evaluating their response 
to therapy. The outcome may be useful in the prevention of hypoglycemia and ad-
justing medications (especially dosage of prandial insulin). It helps to achieve gly-
caemic goals for clients, using irregular insulin injections, medical nutritional thera-
py and non-insulin therapy. (American Diabetes Association 2008b.) 
A1C (Glycated haemoglobin): This should be done two or more times a year for 
patients with stable glycemic control. It should be done periodically for patient that 
are not achieving glycemic goals or changed therapy. The point-of-care testing in 
A1C grants proper decision when needed on therapy changes. (American Diabe-
tes Association 2008b.) 
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4 DIET THERAPY 
The main goal in treating type 2 diabetics is to gradually improve the glycemic con-
trol which includes both pharmacological approach and diet therapy-non- pharma-
cology approach (American diabetes association 2008a). Diet therapy includes 
both healthy nutrition and healthy weight. Healthy meal means eating food from all 
the food groups, low calories and taking the same amount of carbohydrate at each 
meal (Medlineplus 2015a.) 
It is said that the comprehensive way to reducing the glucose level is to eat low 
carbohydrate food. Patient with diabetes type 2 should eat carbohydrate from fruit, 
vegetables, low fat milk and whole grains. Also should monitor their carbohydrate 
level by counting the amount of carbohydrate in their food content. (American dia-
betes association 2008a.) 
4.1 Carbohydrate 
For maintaining glucose balance, large amount of carbohydrate is consumed and 
it will increase the required amount of insulin secretion. Insulin secretion by beta-
cells is glucose sensitive and a high intake of carbohydrate in relation to energy 
intake produces higher post-prandial insulin levels. It is possible that repeated 
stimulation of a high insulin output by a high carbohydrate diet could speed up an 
age-related decline in insulin secretion and lead to an earlier onset of type 2 diabe-
tes. However, the quality and quantity of carbohydrate can urge this response 
(Mann 2006). The most important source of carbohydrate is from vegetables, leg-
umes, whole-grain cereals and fruits and a person total energy intake should con-
tain about 45-60% of this while free sugars such as fruit juice and sugary drink 
should be no more than 5%. (The Scientific Advisory Committee on nutrition 
(SACN).   
Additionally, carbohydrate needs to be monitored in other to obtain glycemic con-
trol like counting carbohydrate in meal, exchanges and experience-based estima-
tion. Meal containing sucrose can be replaced by other carbohydrate food or if 
taken insulin or lowering glucose medication should be used after the meal. Too 
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much of energy intake should be avoided. The recommended dietary allowance 
for carbohydrate is 130g/day (American diabetes association 2008a.) 
4.2 Protein 
The dietary intake of protein should not be more than 20% of energy this is the 
same for patient without diabetes type 2, different studies have shown that glucose 
that are produced from ingested protein does not increase plasma glucose con-
centration but produces more serum insulin response. (American diabetes associ-
ation 2008a) 
4.3 Fat 
(American diabetes association 2008a) recommends that patient should increase 
their intake of long-chain omega-3 fatty acids-EPA-Eicosapentaenoic acid and 
DHA-docosahexaenoic acid for example, fatty fish, and omega-3 linolenic acid 
ALA-alpha-linolenic acid. Fish (particularly fatty fish) should be eaten at least two 
times (two servings) each week. The amount of dietary saturated fat, cholesterol, 
and trans-fat recommended for people with diabetes is the same as that recom-
mended for the general population. High level fat meal should be reduced such as, 
fat pies, pastries, sausages, burgers and other processed meat, full-fat dairy 
foods, cakes, crisps, chocolate should be reduced. (Clark 2014). In addition, satu-
rated fatty acids and trans-unsaturated fatty acids is said to be below 10% of an 
individual’s total energy (or below 8% if low-density lipoprotein [LDL] cholesterol is 
raised) these fatty acids has effect on insulin resistance and the increase insulin  
sensitivity recognized when unsaturated fatty acids are replaced by cis-
unsaturated fatty acids. (Mann 2006). 
4.4 Fiber 
The intake of food that are naturally rich in fiber should be about 40 g/d (or 20 
g/1000 kcal/d), this recommendation was derived from a random trail on type 1 
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and type 2 diabetes but this can vary due to individual beneficial effect. Around 
half of total dietary fiber should be soluble. This type of diet does not only improve 
glycemic control but also produce an increase in high density lipoprotein choles-
terol level and reduces the low density lipoprotein cholesterol level. Food contain-
ing high soluble fiber has a low glycemic index. It is also stated that a meta-
analysis within diabetes subject shows the percentage of hemoglobin A1c of aver-
age 0.43% lower in those consuming a diet of low-glycemic-index foods than in 
people eating a diet of high-glycemic index foods. (Mann 2006). 
4.5 Alcohol 
It has been said that alcohol raises the risk of low blood sugar (hypoglycemia) for 
patient that take tablet or insulin to control their diabetes. Limited amount of alco-
hol can be taken, but blood sugar level can be affect if alcohol is taken with an 
empty stomach. Liqueurs contain high level of sugar and they must be avoided 
(Nazarko 2011). Daily intake should be about one drink for women and two drinks 
for men. If alcohol is taken with carbohydrate substance it may raise the blood glu-
cose but may not have affect alone when consumed moderately. (American diabe-
tes association 2008a). 
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5 MEDICATION / DRUG THERAPY FOR TYPE 2 DIABETES 
Pharmacological interventions or medication therapy are required in the treatment 
of type 2 diabetes when lifestyle modification alone proves insufficient to improve 
the glycemic control/index and reduce the risk of cardiovascular complications. In 
type 2 diabetes, important risk factors include central obesity, age and decreased 
physical activity among adultS. (Capriotti 2005, 341.) The National Institute for 
Health and Care Excellence (NICE 2009) provides guidelines for type 2 diabetes 
management and states that the first line in drug treatment for type 2 diabetes is a 
class of oral anti-diabetic agents, namely: metformin, insulia secretagodues and 
acarbos, which is collectively known as oral glucose control therapies. This is 
started as a mono-therapy (e.g. metformin only), then continued as a combination 
therapy (e.g. metformin+ sulphonylurea) if a desired blood glucose level or a gly-
cated hemoglobin (HbAIC >= 6.5%) is not achieved. 
The second line drug treatment for type 2 diabetes is other oral agents (e.g. Di-
peptidylpeptidase-4 (DPP-4) inhibitor, thiazolidinediones) and Glucagon-Like Pep-
tide-1(GLP-1) receptor agonist. These drug(s) are introduced when the control of 
blood glucose level remains and / or becomes insufficient, or if the patient does 
not tolerate the first line drug therapies. The final stage is the initiation of insulin 
therapies or/ and combining insulin with an oral agent when the oral therapies fail. 
(NICE 2009.) 
5.1 Oral and anti-diabetics agents 
The Treatment of diabetes type 2 with oral anti-diabetic agents concentrates on 
reducing fasting and post meal hyperglycaemia as well restoring and maintaining a 
good glycaemic control. The major classes of oral anti-diabetics agents for the 
treatment of type 2 diabetes have different modes of action, safety profiles and 
tolerability. These classes include agents that spur insulin secretion, increase insu-
lin action, minimize hepatic glucose production and delay digestion and absorption 
of intestinal carbohydrates. Oral anti-diabetic agents should be started with a low 
dose, then after the measurement of glycosylated hemoglobin (HbA1c) which is 
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done by self-monitoring of capillary blood glucose by some patients, the dose may 
then be titrated up conforming to the glycemic response. The major classes of oral 
anti-diabetic agents have usually had a comparable average glucose-lowering ef-
fect, thus about an average of 1–2% reduction in HbA1c. It is an essential doctrine 
to modify treatments according to individual patients and doses must be titrated up 
steadily according to response. (Krentz & Bailey 2005, 386-387.) 
5.1.1 Insulia Secretagodues 
Insulia secretagodues consist of drug groups called sulphonylureas and rapid- act-
ing prandial insulin releasers also known as meglitimide analogues. 
Sulphonylurea has been largely used for half a century for type 2 diabetes treat-
ment. These agents stimulate the secretion of insulin from the β-cell of the pan-
creatic islet, thereby lowering blood glucose levels. They are very effective when 
used early after type 2 diabetes diagnosis and are also regarded as good first line 
oral drugs for patients who, despite using non pharmacological measures (e.g. 
diet, exercise), have not achieved or cannot maintain a desired glycaemic index 
and are not over weight. They are cheap and when properly used, are safe and 
tolerable. Excluding other insulin secretagodues, they can also be used as combi-
nation therapy with other anti-diabetic agents. However, they can cause hypogly-
caemia due to their ability to inhibit glucose production and stimulate insulin re-
lease at a low glucose level. They also have a side effect of increased appetite, 
unwanted weight gain and provoke long term cardiovascular disease risk. (Krentz 
& Bailey 2005, 390-395.) 
Rapid-acting prandial insulin releasers (meglitimide analogues) are taken 
with meals or 30 minutes before meals, thus three times daily to stimulate fast but 
momentary insulin secretion. They improve fasting hyperglycaemia as well as low-
er postprandial glucose levels. They can be used as mono-therapy or as a combi-
nation therapy with other class of oral anti diabetic agents. Meglitimides can be 
helpful drugs for mild to moderate renal impairment patients but a small increase 
in weight could be expected. They are quite more expensive and have a lower risk 
of hypoglycaemia than sulphonylureas. (Capriotti 2005, 345.) 
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5.1.2 Insulin Sensitizers 
These agents act directly against insulin resistance which is the main symptom of 
type 2 diabetes. It is made up of thiazolidinediones and biguanides (metformin). 
Thiazolidinediones (glitazones) enhance the whole body insulin sensitivity by 
stimulating a nuclear receptor called peroxisome proliferator-activated receptor γ 
(PPARγ). The only thiazolidinediones the European Medicine Agency (EMEA) ap-
proved of are pioglitazone and rosiglitazone, though using them as a combination 
therapy with insulin is still contraindicated. (Krentz & Bailey 2005, 404-408.) Thia-
zolidinediones reduce glucogenesis in the liver and increase glucose uptake in the 
skeletal muscle. It also reduces the concentration of plasma insulin. They have no 
risk of hypoglycaemia when used as mono-therapy, hence it can be used as a re-
placement drug if a patient has contraindication for, or is intolerant to metformin. 
They are also used as a combination therapy with other oral agents for obese or 
non- obese type 2 diabetes patients. The major possible risks to take into consid-
eration when using thiazolidinediones are oedema, weight gain, bone fracture and 
anaemia. Diabetic patients with dyslipidaemia should not use thiazolidinediones 
because of their effect of increasing total cholesterol and LDL cholesterol levels.  
Patients with evidence of congestive heart disease or heart failure are contraindi-
cated to the use of thiazolidinediones. (Capriotti 2005, 344.) 
Biguanides (metformin) is one of the cheapest and most recognizable oral anti-
diabetic drug available. Most type 2 diabetes patients widely regard metformin as 
a foundation of oral therapy or as an add- on to some patients on other treatments, 
such as sulphonylureas. Minimizing the production of an enormous amount of he-
patic glucose is the dominant action of metformin. It increases hepatic sensitivity, 
coordinates cellular energy as well as glucose and lipid metabolism. It exhibits 
glucose lowering actions without causing overt hypoglycaemia and weight gain, in 
some cases it enhances weight loss in obese patients. Glucose uptake by the 
skeletal muscle is also increased by metformin. The potential adverse effects, 
however, include anorexia, impaired absorption of vitamin B12, gastrointestinal 
disturbance and sometimes lactic acidosis. (Capriotti 2005, 343.) 
Metformin can be used as a mono-therapy or in combination with other oral anti-
diabetic drugs and insulin, but it is contraindicated in patients with renal failure, 
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cardiac or respiratory problems, liver disease, metabolic acidosis history, alcohol 
abuse or any other condition that may lead to hypoxia. The initiating dose for chil-
dren is one tablet of 500mg once / twice daily with meal and this may be increased 
at weekly intervals by 500mg. Depending on the country, the maximum dose for 
an adult is 2.55-3.0g daily (Krentz, Bailey & Patel 2008, 2134-2317.) 
5.1.3 Alpha-Glucosidase Inhibitors 
The alpha- glucosidase inhibitors available include miglitol, voglibose and acar-
bose being the most common. They have a good safety record of reducing post-
prandial hyperglycaemia by slowing down the digestion of carbohydrate, without 
causing weight gain or hypoglycaemia. They can minimize postprandial hyper-
insulinaemia and some studies have proven that they have plasma triglyceride 
lowering effects. The most common side effect of alpha-glucosidase inhibitor 
agents is the gastrointestinal agent. (Krentz, Patel & Bailey 2008, 2138-2319). 
5.2 Incretin-Based Therapy 
Incretin therapy is a glucose lowering therapy based on the incretin hormone GLP-
1 which is released from the endocrine cell in the gut during and after meal inges-
tion. GLP-1 contributes to the large secretion of insulin after meal ingestion which 
is associated with developed glucose-stimulated insulin secretion by intestinal 
hormones and called incretin effect.  Incretin therapy action of stimulating insulin 
secretion and inhibiting glucagon secretion in the   long run lowers fasting plasma 
glucose and fasting postprandial with a very low hypoglycaemic risk and no weight 
gain.  A major challenge of GLP-1, however, was that it was inactivated quickly by 
an enzyme DPP-4 produced in the endothelial cell ,thereby making the circulating 
half- life of GLP-1 one to two minutes only. In order to overcome the effect of DPP-
4, GLP-1 receptor agonist (DPP-4 resistant) and DPP-4 inhibitor were developed. 
(Ahren 2013, 31.) 
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5.2.1 Glucagon Like Peptides-1 (GLP-1) and GLP-1 Receptor 
Agonist/Inhibitor 
Glucagon-like peptide (GLP-1), though found to be the most powerful insulin 
stimulator, still had poor response on people with Type 2 Diabetes. Therefore, 
GLP-1 agonists were developed to lengthen and upgrade GLP-1’s activity of re-
ducing blood glucose levels.GLP-1 agonists are now licensed for use in type 2 
diabetes. These agents are injectable therapies, given subcutaneously (Ahren, 
2013, p 31). GLP-1 agonist only works if there is glucose available to work with. 
This direct relationship to oral glucose load means that their hypo-glycaemia (hy-
po) risk is very low, hypo-glycaemia only increases when GLP-1 agonists are used 
with other drugs known to cause hypos. GLP-1 agonist has a wide range of effects 
among which there are; reduces both fasting and postprandial glucose levels 
which stimulates the secretion of glucose dependent insulin and suppresses the 
inappropriate elevation of glucagon; It also leads to weight and systolic blood 
pressure reduction. (Pratley 2008, 8.); It also hinders glucose neo-genesis in the 
liver and slows down the digestion process, hence delays gastric emptying leaving 
the patient feeling fuller for longer which leads to weight loss in some patients. 
(Ahren 2013, 31.) 
 GLP-1 receptor agonists are safe and highly tolerable with the only persistent ad-
verse reaction being nausea and vomiting, which appears mostly only in the early 
weeks after therapy has begun. There are now four different types of GLP-1 ana-
logues available: the original exenatide (Byetta) 5-10mcg is injected subcutane-
ously twice daily, the newer longer-acting version of exenatide 2 mg (Bydureon) is 
injected once weekly, liraglutide (Victoza) 0.6-1.2 mg and lixisenatide (Lyxumia) 
10-20 Meg, are both injected once daily. Both exenatide and liraglutide when used 
as add on to metformin, sulphonylurea and thiazolidinedione, result in reduced 
HbA1c, fasting and prandial glucose as well as body weight. (Ahren 2013, 31.) 
Liraglutide also comes in a dose of 1.8mg but this is not often used and is not en-
dorsed by NICE (2010) in the treatment of diabetes, unless recommended by a 
specialist. The NICE (2009) guidelines also state that any patients treated with a 
GLP-1 should ideally achieve a glycaemic improvement of about 10 mmol/mol 
(1%) and/or a weight loss of 3% in the first 6 months of treatment. Failure to 
23(55) 
 
achieve one of these targets means the treatment should be reviewed as it may 
not be cost-effective. Failure to reach either target should result in the treatment 
being stopped. 
5.2.2 Dipeptidylpeptidase-4 (DPP-4) Inhibitor 
DPP-4 inhibitors are oral tablets taken once or twice daily, developed to prevent 
the activity of the DPP-4 enzyme and prolong and strengthen the activities of GLP-
1. The first study that showed the possibility of using DPP-4 was tested for a peri-
od of four weeks and the result was that it showed a reduction in both prandial and 
fasting blood glucose as well as HbA1c. DPP-4 inhibitors can be used as a mono-
therapy, as well as in combination with metformin, sulphonylurea, thiazolidinedione 
and insulin. Regardless of how it is used, there was improvement in glycaemia 
without weight gain or even with a slight reduction in weight with very low risk for 
negative effects including hypoglycaemia. DPP-4 inhibitors, such as sitagliptin 
(Januvia), vildagliptin (Galvus), saxagliptin (Onglyza) and linagliptin (Trajenta) are 
now clinically used in a lot of countries by patients. (Ahren 2013, 32.) Table 1 
summarises the differences and similarities of the effects of DPP-4 inhibitor and 
GLP-1 receptor agonist. 
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Table 1. Differences and similarities between GLP-1 receptor agonist and DPP-4 
inhibitor (Blonde 2011). 
 
5.3 Selective Sodium Glucose Co-transporter 2 Inhibitor (SGLT2-i) 
Selective sodium glucose co-transporter 2 inhibitor (SGLT2-i), also known as gli-
flozin, is a new class of glucose lowering drugs approved for mono-therapy, but 
mostly used in combination with metformin or other glucose lowering agents. They 
reduce glucose reabsorption and increase urine excretion by inhibiting the SGLT2 
in the proximal nephrone. Thus, it reduces blood glucose level b increasing the 
outflow of blood sugar (glucose) in urine. They reduce HbA1c by 5.5-11 mmol/mol 
(0.5-1.0%) and can be used at any stage of type 2 diabetes because their action is 
independent of insulin (Diabetes care, 2015). It safely and moderately reduces 
weight, FPG as well as systolic and diastolic blood pressure and has very low or 
no risk of hypoglycaemia. The side effects however are: worsened polyuria, dehy-
dration, osmotic diuresis, urinary tract infections and Volvo-virginal infections. Pa-
tients already using diuretics and elderly patients should use this agent with cau-
tion. (ADA, 2015.) 
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5.4 Insulin Therapy 
Insulin therapy was usually initiated by practitioners in a / the majority of type 2 
diabetes patients in order to reach a desired and optimal glycaemic control 
(HbA1C <6) when the combination of non- insulin therapies and changes in life-
style do not produce a satisfactory glycaemic control. Different kinds of individual 
factors, such as type of diabetes, the patient’s degree of interest, patient needs, 
presence of diabetic complications (e.g. blindness), patient’s job and financial situ-
ation etc. influence the decision to start insulin therapy, and a final decision should 
be made only after having a full discussion with the patient about it. A potential 
insulin therapy’s side effect of hypoglycaemia and weight gain, as well as patient’s 
own reluctance to monitor blood glucose and needle phobia, are the common rea-
sons why some patients want to or try to avoid insulin therapy. Some patients also 
believe insulin therapy is a sign that they have failed in their treatment and would 
rather prefer to live with poor glycaemic control instead of starting insulin injection. 
Therefore, it is the duty of the health care professional to educate and help pa-
tients accept and start insulin therapy in order to succeed. Oral anti-diabetics such 
as metformin, sulfonylurea, sitagliptin, pioglitazone may still be continued while 
using insulin, unless contraindicated. (Morris 2011, 496.) Insulin therapy generally 
consists of three insulin regimens, namely: basal, prandial and premixed insulins.  
Basal Insulin is the most common starting point for insulin therapy initiation con-
sisting of glargine, determir and neutral protamine hagedorn (NPH) and a dosage 
of once daily. They reduce preprandial glucose level, minimize the level of fasting 
glucose and weight gain with a  low risk of both nocturnal and prebreakfast hypo-
glycaemia. This is achieved by basal insulin’s function of indicating the amount of 
insulin required to minimize the liver’s production of glucose and maintain good 
glucose levels between meals. (Spollet 2012, 254.) Basal insulin is usually started 
when the HbA1c level is less than about 9.5%. (Morris 2011, 497.) 
Prandial Insulin (Rapid & short- acting insulin) according to Spollet (2012, 254-
256) is short-acting insulin administered as a bolus to regulate postprandial hyper-
glycaemia. It is given before meal as a replacement therapy for basal insulin, or as 
an add- on therapy to the basal insulin. This has a quicker onset effect with a 
shorter acting time, hence producing a great reduction in the glycaemic levels. The 
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actions of the prandial insulin could be fast and / or short. The fast /rapid acting 
prandial insulin should be taken during meals, while the short acting prandial insu-
lin should be injected 30 minutes before meal. There is an increased risk of hypo-
glycaemia if prandial insulin is not injected at the right time. Types of prandial insu-
lin analogues include: insulin aspart (novolog), glulisine (apidra) and lispro (Hu-
malog). (Boyle 2008, 384.) Morris (2011, 497) stated that this is given or intensi-
fied when basal insulin does not achieve the required glucose level or when the 
HbA1c level is greater than 9.5%. 
Premixed Insulin Therapy is a premixed combination of a fixed dose of basal and 
regular or analog rapid-acting insulin used twice or thrice daily with meals, if great-
er control is required. Patients may, however, switch back to the basal-bolus ther-
apy if an excellent or desired glucose control is not achieved after two or three 
premix insulin injections. Premixed insulin also has a high risk of hypoglycaemia if 
not used at the right time. (Spollet 2012, 255). According to NICE (2009), pre-
mixed insulin therapy  should be considered if a patient’s HbA1C>=9. 
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6 THE GOALS AND PURPOSE OF THE THESIS 
The goals of the thesis were to find out the treatment of diabetes focusing on the 
drug and diet therapy in Finland compared to United States of America. In addi-
tion, authors of this thesis wants to find out how effective this treatment is in Fin-
land as compared to the United States and how nurses can assist patients in the 
management/treatment of diabetes.  
The purpose of the thesis was to find out the possible differences and similarities  
in the treatment of type 2 diabetes in Finland and the United States focusing on 
diet therapy (eating habits, exercise) and medication therapy(insulin, oral dugs, 
follow up blood sugar tests) based on the evidence based articles, journals, text-
books, and reliable sources like WHO.  
This thesis explores the difference in the treatment outcomes of diabetes type 2 in 
Finland and the USA and the role of nurses, family members, health care practi-
tioners and type 2 diabetes patients themselves in the treatment of diabetes. 
The research questions of this thesis were: 
What are the differences and or similarities between Finland and the USA in their 
diet and medication therapy treatment of type 2 diabetes?.  
After the treatment of diabetes in both countries what are the differences in the 
outcome?. 
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7 THESIS IMPLEMENTATION 
7.1 Literature review 
The method used for data collection in this thesis was the literature review. Hart 
(1998 as stated in Cronin, Ryan & Coughlan 2008, 38) defines literature review as 
an objective, detailed or comprehensive summary and critical analysis of important 
researches and non–research literature on a topic being studied (Cronin, Ryan & 
Coughlan 2008, 38). Literature review can also be a simple summary of infor-
mation published on a particular subject within a period of time. The discussed 
published information is coordinated in a pattern that combines both summary of 
the source’s important information and the reconstruction or reorganization of the 
whole information. (The writing centre 2012.) 
A good literature review is well written and incorporates if any, only a few personal 
prejudices. Literature review is a five step process, with the first step being identi-
fying the subject of the literature review or selecting a topic for review. The second 
step is to search for the literature of the review topic using journals, books and 
publications and / or computers as well as appropriate electronic databases with 
keyword searches or alternative keywords with similar meanings (synonyms) that 
might evoke further information on the topic. The third step is to read and analyse 
the literature that has been gathered. This is done first by an initial overview of the 
articles, which mostly is done by reading the abstracts or summarises at the be-
ginning of the papers. This helps to decide which articles are worthy of further 
reading. It is followed by a more critical and systematic review of the content of the 
chosen articles. The fourth step is writing the review. In order to write a good re-
view after reading and analysing the literature, findings must be presented in a 
clear and logical way while considering the research questions at every decision. 
The last step is to mark all the references that were used in the research. This will 
create a complete background together with the information written about the cur-
rent knowledge of the research topic or study reviewed. (Cronin, Ryan & Coughlan 
2008, 39-42). 
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A thorough search for the research articles was done using CINAHL and SAGE 
data bases as well as other reliable online sources and publications. This search 
was limited to full text sources only in Finnish and English languages. The search 
outcomes were reduced to articles published from 2004 to 2015. 
7.2 Data collecting process 
The data collecting process proceeded according to the literature review process. 
The keywords used to search for information were diabetes, diabetes type 2, diet 
therapy and drug therapy. 
Diabetes: This is a condition or a disease in which the blood sugar, or blood glu-
cose levels are too high. Diabetes when not properly controlled or managed can 
lead to major damage of the body systems. (WHO 2015) 
Diabetes type 2: This condition occurs when the body does not produce enough 
insulin or the insulin produced is not effectively used by the body. Diabetes type 2 
is also known as adult onset diabetes and it is usually occurs as o result of physi-
cal inactivity and excess body weight. (WHO 2015). 
Diet therapy: This involves treatment of a disease by regulating the whole diet. 
The diet regulated includes daily amount as well as the kind of food and drink tak-
en in by a person (The free dictionary 2015 a). 
Drug therapy: This is also known as pharmacotherapy. It is the use of drugs in the 
treatment of disease (The free dictionary 2015 b) 
7.2.1 Choosing the topic for review 
Choosing a topic for review was the first step in this thesis writing, as it is required 
in order to begin collecting data for the thesis. The authors of this thesis chose to 
write about the diet and medication therapy in the treatment of type 2 diabetes. 
The focus was on the diet recommendations for type 2 diabetes patients, as well 
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as the different kinds of type 2 diabetes drug/medication therapy, their effect and 
when to initiate them on patients. 
7.2.2 Inclusion and exclusion criteria 
Appropriate keywords related to the thesis topic were used as search words, and 
the result outcome were restricted by choosing inclusion and exclusion criteria. 
This helped to achieve useful and up-to-date information for the thesis and also 
reduce the number of result articles to a manageable size. The data search was 
restricted by choosing only full text articles, published literature and the articles 
had to be peer reviewed. All the articles and information used were no more than 
ten years old. Table 2. explains more about the inclusion and exclusion criteria. 
Table 2. Inclusion and Exclusion criteria used in the data search of the thesis.  
Inclusion Criteria Exclusion Criteria 
Published literature Non- published literature 
Language: English and Finnish Language: Other languages 
Free articles Non- free articles 
Articles with abstract Articles with no abstract 
Published in year 2004 or later Published before 2004 
Peer reviewed articles Non- peer reviewed articles 
Full text articles Non- full text articles 
Scientific articles  
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7.2.3 Data search result 
CINAHL with full text and SAGE were the electronic databases used for data 
search to write this thesis. “Type 2 diabetes” AND “Diet therapy”, “Diabetes type 2” 
AND “Drug therapy” were the search words used to search for articles in both da-
tabases used and each yielded quiet a large number of search results. The basic 
inclusion and exclusion, such as full text articles  published from 2004 were 
marked beforehand. 
CINAHL with full text database was used twice to search for articles, each time 
using different keywords. The first search word used in CINAHL was “type 2 diabe-
tes” AND “diet therapy”, the search results’ outcome were 98 articles.  After read-
ing the title, 88 articles were included while were 10 were excluded.  Also, after 
reading the abstract and the introduction, 29 articles were included from the 88 
articles. After reading through, 21 articles were excluded and 7 were included.  
After reading thoroughly, all the 7 articles were used in the thesis.  The second 
search word was “diabetes type 2” AND “drug therapy”. The search results’ out-
come for this search word was 363 articles. 82 articles were included after reading 
through all the titles of the search result outcome. Furthermore, 30 articles were 
included after reading the abstracts of those 82 articles. Finally, after thoroughly 
reading through and reviewing the 30 chosen articles, 19 were excluded and 10 
were found to be relevant to the thesis topic and were included in the final thesis. 
CINAHL with full text database search process of both search words, including 
how the inclusion and exclusion criteria were used to get the required articles, are 
shown in the figures 1 and 2. 
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Figure 1. The first search results from CINAHL. 
 
CINAHL with full text
Type 2 diabetes and diet therapy.
Number of articles found
98
Included after reading titles.
88
Included after reading abstract
29
Included after  
reading article
7
Excluded after 
reading article
21
Excluded after 
reading abstract
59
Excluded after 
reading titles
10
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Figure 2.The second search results from CINAHL. 
 
SAGE database was also used twice to search for articles, each time using 
different keywords. The first search words used in SAGE were  “Type 2 diabetes” 
AND “Diet therapy, and the second search words were “diabetes type 2” AND 
“drug therapy”. However, no article from SAGE was included in the writing of the 
thesis  after using the inclusion and exclusion criteria as well as reading the titles, 
abstracts and articles. The search results for both search words when SAGE 
database was used is provided in figure 3 and figure 4. 
CINAHL with full text
Diabetes type 2 and drug therapy
Number of articles found
363
Included after reading titles
82
Included after reading abstract
30
Included after 
reading article
10
Excluded after 
reading article
19
Excluded after 
reading abstract
52
Excluded after 
reading titles
281
34(55) 
 
 
Figure 3.The first search results from SAGE 
 
SAGE database
Diet and diabetes type 2
Number of articles found
20
Included after reading titles
12
Included after reading abstract
2
Included after 
reading article
0
Excluded after 
reading article
2
Excluded after 
reading abstract
10
Excluded after 
reading titles
8
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Figure 4. The second search results from SAGE. 
 
In conclusion, a total of 17 articles from CINAHL and SAGE databases, in addition 
to other reliable online publications and webpages from free internet such as 
WHO, ADA, IDF, ACCE, NICE, medlineplus, terveyskirjasto etc. were used in the 
writing of this thesis. 
7.3 Content analysis 
Content analysis is a method used to analyse qualitative and / or quantitative data 
in a deductive or inductive way. Inductive content, which is recommended if there 
is not enough former knowledge about a subject or if the knowledge is fragmented 
(Elo & Kyngäs 2008), is the content analysis process used in this thesis. 
Generally, there are three main phases in either the deductive or inductive content 
analysis process, namely: preparation phase, organisation phase and reporting of 
SAGE database
Diabetes and drug therapy
Number of articles found
35
Included after reading  titles
4
Included after reading abstracts
2
Included after 
reading 
articles
0
Excluded after 
reading 
articles
2
Excluded after 
reading abstracts
2
Excluded after reading  
titles
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results phase. The preparation phase involves collection of data to be analysed. 
The next phase is the organisation phase, where the data collected are read, un-
derstood, interpreted and coded in a valid and reliable way. According to Polit & 
Beck (2004 as referred to by Elo & Kyngas 2008), in this stage, in order to become 
totally submerged into the data, it is important to read through the material several 
times and note the key question when reading the data and material. The ques-
tions are: What is happening? When did it happen? Where is this happening? Who 
is telling? and Why?. The reporting of results or found information is the last phase 
of content analysis (Elo & Kyngas 2008). 
7.3.1 Data analysing process 
This thesis was conducted using the inductive content analysis method. Data re-
lated to diabetes, diabetes type 2, drug therapy and diet therapy were searched 
and the articles or materials related to the topic were selected and read. The data 
was then organised by making notes and headings in the text while reading was 
going on. The chosen articles were read through several times focusing on points 
needed to provide information for the thesis writing. Questions stated by Polit & 
Beck (2004 as referred to by Elo & Kyngas 2008)) were noted and some an-
swered. As many headings as necessary were written down in the margin to de-
scribe all aspects of the content and sub-categories and generic categories were 
freely generated from these headings. The data analysis process used in the the-
sis is shown in table 3. 
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Table 3. Result categories of the thesis. 
Sub-Categories Generic Categories Main Category 
Food and eating princi-
ples 
Obesity in diabetes 
Lifestyle modification 
 
Similarities and differ-
ences in the diet therapy 
between Finland and the 
USA. 
General guidelines on the 
treatment and manage-
ment of type 2 diabetes. 
 
Oral antidiabetic agents 
Glycaemic control algo-
rithm in the treatment of 
type 2 diabetes.  
Insulin therapy. 
Other antidiabetic agents. 
 
Similarities and differ-
ences in the drug therapy 
between Finland and the  
USA 
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8 RESULTS 
The results of this thesis answer the research questions concerning the differ-
ences and similarities between Finland and the USA in their treatment of type 2 
diabetes, as well as the possible differences in the outcome of their treatments. 
The results also show the general guidelines necessary for nurses, patients and 
their caregivers (e.g.family) in the management of type 2 diabetes.  
Individuals suffering from diabetes have their own metabolic profile, treatment 
goals, possible outcomes/recovery, eating habit and choices of food, which is why 
the nutritional therapy must be categorized.  Monitoring the metabolic parameters, 
including glucose, HbA1c, lipids, blood pressure, body weight, and renal function 
when applicable. The quality of life is also essential to assess the need for chang-
es in therapy and to ensure successful outcomes. Continuous nutrition self-
management education and care needs to be available for individuals with diabe-
tes. (American Diabetes Association 2004.) 
8.1 General guidelines on the management of type 2 diabetes. 
Following the WHO and ADA criteria, the results of one or all of these following 
three tests can be used to diagnose diabetes type 2: the fasting plasma glucose 
(FPG) ≥ 7.0 mmol/l (126 mg/dl), or oral glucose tolerance test (OGTT) 75g with 2 
hour plasma glucose ≥ 11.1 mmol/l (200 mg/dl), or glycated haemoglobin (HbA1c) 
≥ 6.5% / 48 mmol/mol, or  random plasma glucose (RPG) ≥ 11.1 mmol/l (200 
mg/dl) in the presence of  diabetes symptoms (WHO 2006). Asymptomatic individ-
uals with a single abnormal test should have the test repeated to confirm the diag-
nosis unless the result is unequivocally elevated. When a random plasma glucose 
(RPG) level is ≥ 5.6 mmol/l (≥ 100 mg/dl) and < 11.1 mmol/l (< 200 mg/dl) is de-
tected, a FPG should be measured, or an OGTT performed, or an HbA1c meas-
ured and evaluated after three months in order to accurately diagnose the pres-
ence of diabetes. Lifestyle modifications and control of hyperglycaemia, blood 
pressure and cholesterol are important in the management of diabetes. (IDF 
2012.) 
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The management of type 2 diabetes should be patient centred. Patients should 
receive formal education on how to take care of themselves and how they will be 
taken care of, such as the need for a change in lifestyle (diet + exercise + smok-
ing), self –glucose monitoring, carbohydrate counting, possible future care (oral 
medication and insulin therapies) as well as possible diabetes associated compli-
cations and how they can be managed or prevented. Such education should start 
almost immediately after the diagnosis and throughout the care that will be given. 
People with diabetes should be advised that it is important to achieve and maintain 
an HbA1c below 7.0% / 53 mmol/mol, so the risk of developing complications is 
minimised. For patients with co-morbidities and or history of hypoglycaemia due to 
an attempt to optimise control, a higher HbA1c target may be considered. For dia-
betic patients HbA1c level should be regularly checked taking into account bene-
fits, safety and tolerability. The on-going care or treatment should be reviewed and 
modified if HbA1c level is above or below the agreed target on two consecutive 
occasions. Advice should be given to patients in whom the target HbA1c levels 
cannot be reached that any improvement is beneficial (IDF 2012). Table 4 shows 
the equivalent values for HbA1c and capillary plasma glucose. 
Table 4. Values for HbA1c and plasma glucose level. WHO and ADA criteria.  
(WHO 2006; ADA 2014). 
 Normal level Diabetes  level 
HbA1c <6.0% / 42 mmol/mol ≥ 6.5% / 48 mmol/mol 
Fasting plasma glucose 
(FPG) 5.5 mmol/l (100 mg/dl) ≥ 7.0 mmol/l ( 126 mg/dl) 
2 hours Post meal plasma 
glucose or RPG in the 
presence of symptoms 
<200 mg/dl (11.1 
mmol/l) ≥ 200 mg/dl (11.1 mmol/l) 
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8.1.1 Diabetes and treatment of type 2 diabetes in Finland 
In Finland, over about 250,000 people (Finns) have type 2 diabetes (Diabetesti-
etoa 2015a). The treatment for type 2 diabetes starts with diet and exercise. Medi-
cation therapy is initiated when a desired hb1Ac value is not achieved with diet 
and exercise only. The treatment of type 2 diabetes is carried out mainly by the 
patient, thus the patient’s willingness to modify his or her life style, since life style 
modifications such as healthy eating habits and regular exercise are very im-
portant in the treatment and management of type2 diabetes. Nurses and health 
care professionals provide the diet and exercise guidelines. The doctor decides 
the kind of medication to be administered alongside the life style modification 
treatment. If the patient is very obese, then bariatric surgery is advised or sug-
gested to patient. Upon patient agreement, it is done to make the patient lose 
about 30 to 40 kilograms of their weight, which sometimes helps completely with 
their diabetes cure or restore their blood sugar level back to normal without any 
medication (Terveyskirjasto 2015). Finland uses the criteria for diabetes diagnosis 
provided by the World Health Organisation (WHO) and American diabetes associ-
ation (ADA) in the diagnosing of diabetes (Kaypahoito 2015.) 
8.1.2 Diabetes and treatment of type 2 diabetes in the USA 
The seventh leading cause of death in the USA now is diabetes mellitus. Type 2 
diabetes affects about 90-95% of their population suffering from diabetes 
(Qaseem, Humphrey, Sweet, Starkey & Shekelle 2012). The treatment of diabetes 
is started with patient education and lifestyle modification. When the result is not 
enough, pharmacotherapy is then introduced. Pharmacotherapy is initiated as an 
add-on therapy to the lifestyle modification and can be adjusted based on patient 
response. The targeted HbA1c level for patients with low risk of hypoglycaemia 
and no coexisting serious illness is ≤6.5%. However, based on factors such as 
age, co-morbid conditions, duration of diabetes, risk of hypoglycemia, patient mo-
tivation, adherence, and life expectancy, care given and HbA1c target level is indi-
vidualized for each patient, mostly HbA1c target is > 6.5%. In overweigh diabetic 
patients, obesity is first treated using lifestyle modifications (diet +exercise), medi-
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cations and/or surgery. Generally, lifestyle modification is the first step in the 
treatment of type 2 diabetes. When the desired result (HbA1c ≤6.5%) is not 
achieved with lifestyle modifications only, then oral anti-diabetic medications and/ 
or insulin are added to the treatment. (ACCE 2013, 8-10.) 
8.2 Similarities and Differences in the diet therapy between Finland and the 
USA for diabetes type 2. 
8.2.1 Food and eating principles for type 2 diabetes patients in Finland 
A healthy diet is very important in the treatment of type 2 diabetes, since the major 
cause of type 2 diabetes is an excess amount of fat tissue inside the abdominal 
cavity and the liver, therefore a lot of emphases is placed on diet that helps reduce 
fat from the abdominal cavity relatively more than the skin below. The most im-
portant change in the diet of type 2 diabetes patients is  to reduce their amount of 
energy (carbohydrate) intake,  their level of salt intake should be monitored 
(should not be too high) to help treat diabetes related hypertension and cardiovas-
cular diseases, their amount of saturated fat used is also monitored in order to 
control their blood cholesterol level. Patients are advised to use healthy vegetable 
oils when cooking. 400-500 grams of vegetables, berries and fruits are or should 
be eaten daily (Terveyskirjasto 2015). 
8.2.2 Food and eating principles for type 2 diabetes in USA 
United state department of agriculture food model explains that plate food should 
contain- vegetable (about half of the plate), protein and starch should be one quar-
ter each.  Grain, Beans and Starchy Vegetable- A person should eat six or more 
serving per day. Foods like bread, grains, beans, rice, pasta, and starchy vegeta-
bles are at the bottom of the pyramid because they should serve as the foundation 
of your diet. All together they contain vitamins, minerals, fiber, and healthy carbo-
hydrates. (Medlineplus 2013) 
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It is necessary to eat foods containing a lot of fiber, whole-grain meal like whole-
grain bread or crackers, tortillas, bran cereal, brown rice, or beans. Whole-wheat 
or any form of whole-grain flours in cooking and baking and low-fat breads, for ex-
ample bagels, tortillas.  (Medlineplus 2013) 
Vegetables should be served about 3-5 servings per day. A patient should eat ei-
ther fresh or frozen vegetables without added sauces, fats, or salt. Choose more 
dark green and deep yellow vegetables, such as spinach, broccoli, romaine let-
tuce, carrots, and peppers.  (Medlineplus 2013) 
Fruits must be taken about 2-3 serving in a day, more whole fruit rather than juic-
es; whole fruits have extra fiber. Citrus fruits, such as oranges, grapefruits, and 
tangerines, are the best. Do not take juices that contain added syrups or sweeten-
ers. (Medlineplus 2013) 
Milk choice should be low-fat or nonfat milk or yogurt. Yogurt has natural sugar in 
it, but it can also contain added sugar or artificial sweeteners. Yogurt with artificial 
sweeteners has fewer calories than yogurt with added sugar. (Medlineplus 2013) 
Meat and Fish eaten should regularly be fish and poultry. Make sure to remove the 
turkey and chicken skins because of the fat it produces. Select lean cuts of beef, 
veal, pork, or wild game remove also any visible fats. Patient should avoid frying 
food by baking, roasting, grilling or boil. (Medlineplus 2013.) 
8.2.3 Similarities of drug therapy of diabetes type 2 diabetes in Finland and 
U.S.A. 
Carbohydrate counting is very important when planning the diet of type 2 diabetes 
patients. Carbohydrates are one of the main nutrients found in food and drinks 
which includes starch, sugar and fibre. However, it increases it cases a rise in 
blood sugar level than the other nutrient, Carbohydrate counting helps to control 
the blood sugar level. It has been suggested that carbohydrate intake should be 
from 45-60% total calories. One gram of carbohydrate provides about 4 calories, 
so patient must divide the number of calories you want to get from carbohydrates 
by 4 to get the number of grams. For example, if you want to eat 1,800 total calo-
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ries per day and get 45% of your calories from carbohydrates, you would aim for 
about 200 grams of carbohydrate daily. You would calculate that amount as fol-
lows: 45 x 1,800 calories = 810 calories. 810 ÷ 4 = 202.5 grams of carbohydrate 
(NIH 2014). Table 5 shows the percentage of total intake of nutrients required of a 
diabetic type 2 patient whiles Figure 7 show an example of a daily meal calories. 
Table 5. Percentage of total energy intake. (Diabeetikon Ruokavaliosuositus 
2008). 
Nutrient Form Amount (%) 
Carbohydrate  45-60 
Fat Saturated and trans fatty 
acid. 
Less than 10 
Monosaturated fatty acids 10-20 
Polyunsaturated fatty 5-10 
Protein  10-20 
 
 
Figure 5. Example of a daily meal 300-400kcal ((Diabetestietoa 2015b) 
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Obesity is defined as an abnormal or excessive fat accumulation by the body that 
presents a risk to health. Obesity is measured using the body mass index (BMI) 
scale. This involves measuring a person’s weight (in kilograms) divided by the 
square of his or her height (in metres). Generally an individual is considered obese 
if BMI reads 30 or above whiles those with BMI equal to or more than 25 are con-
sidered overweight (WHO 2015b). Obesity management is essential in the preven-
tion and treatment of type 2 diabetes and its complications. Overweight or obese 
people are at high risk of developing type 2 diabetes. Also being overweight fol-
lowing a diagnosis of type 2 diabetes will raise the risk of future complications.  
Estimation shows that 60–90% of cases of type 2diabetes are directly related to 
obesity. There has been a suggestion that people who are overweight and have 
been diagnosed with type 2 diabetes need significant weight loss through a very 
low calorie diet (600kcalorie/day) or through bariatric surgery, and this may even 
lead to remission of the condition. There has been improvement in the glycaemic 
control and reduction in the risk of developing diabetes in people who have im-
paired fasting glycaemia or impaired glucose tolerance upon moderate weight 
losses (5-10% of starting weight). Over the years, numerous drug options have 
been tried to help people lose weight, but many, as a result of the undesirable 
negative effect (drug reaction), have been withdrawn from the market. Presently 
orlistat is the only medicine which has a license for prescription in the UK to help 
support weight loss. (Thomas & Storey 2013). Recent research into the role of li-
raglutide as a weight loss treatment has now proved promising and may offer an-
other tool in the fight against obesity (NICE 2010). 
Lifestyle modifications, such as weight loss, increased physical activity and im-
proved eating habits are essential in the management of type 2 diabetes. Nurses 
educate patients on the importance of lifestyle modifications in relation to diabetes. 
Guidance on the kinds of healthy foods and eating habits which include no over-
eating, eating only when hungry not when bored or sad, not watching television 
while eating, etc. are taught to patients. Nurses advise and educate patients on 
the effects of smoking and alcohol intake on their health and present condition if 
patients use them. Patients are guided on the kinds of exercise and physical activi-
ties they can engage in that will lead to weight loss. Nurses can also plan with pa-
tients on how they can go about the exercise, either alone, with a friend(s) or 
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group e.g. gym and if it is going to be daily or some days a week. Nurses advise 
patients on how long they can exercise when they do, then how many minutes or 
hour is enough at a time or for a day. Nurses discuss the goal weight with patients 
and the time frame for achieving it, but let patients understand that it is still a pro-
gress if there is a decrease in weight, even if they are not able to achieve the set 
goal. Despite the fact that lifestyle modification alone is unlikely to help achieve an 
adequate glycaemic control, there has been evidence that lifestyle modifications 
can result in prolonged changes in blood glucose levels with the right support from 
healthcare professionals. (Robertson 2012, 278-279). 
8.2.4 Differences 
After reading through many scientific and this thesis topic related articles, authors 
found out that there is no difference in the diet therapy in both countries. Their 
most important focus in the diet of type 2 diabetes patients is to reduce their 
amount of energy (carbohydrate) intake. 
8.3 Similarities and differences in the drug therapy between Finland and 
the USA 
Below 8.2.1 and 8.2.2 will explain how drug therapy for diabetes type 2 is used 
and managed in both Finland and U.S.A. It will also show or emphasize on any 
similarities and or differences these two countries have in their treatment ways 
8.3.1 Drug Therapy (antidiabetics) in Finland 
Oral anti-diabetic agents are the medication initiated in the drug therapy of type 2 
diabetes. In Finland, medication therapy for the treatment of type 2 diabetes is 
usually initiated when HbA1c level is repeatedly about 6.5-7.0% (50 mmol/mol) 
despite patient’s lifestyle modification (exercise and diet) measures. Medication 
therapy is started using oral anti-diabetic agents. Metformin is usually the oral anti-
diabetic agent started as a first line drug treatment for type 2 diabetes patients un-
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less contraindicated (Diabetestietoa 2015a). It is also a starting treatment for 
overweight diabetic patients. It reduces sugar production in the liver. Other oral 
medication may be added to metformin or any first line drug used, if a single agent 
is not effective within 3-6 month. This is known as the dual or combination therapy. 
Insulin therapy is the final treatment when the oral medication, together with the 
lifestyle modifications, still do not help achieve a normal or desired HbA1c level, 
thus HbA1c < 7.0% (53 mmol/mol). The commonly used insulin is the long-acting 
insulin, which is mostly injected in the evenings and the short-acting insulin which 
is injected before meals.  Usually metformin and other oral medication could still 
be continued even when insulin therapy is introduced or initiated (Terveyskirjasto 
2015). It is important to constantly monitor weight, blood pressure and cholestrol 
levels after pharmacotherapy initiation, and also each time a drug is intensified 
(Diabetestietoa 2015a). 
Other oral antidiabetic agents and medication used in Finland besides metfor-
min are sulphonylureas (glibenclamide, glipizide, glimepiride) to increase pancre-
atic insulin secretion. DPP-4 inhibitors (sitagliptin, linagliptin, vildagliptin, sax-
agliptin) are administered once or twice a day depending on the product to in-
crease insulin secretion and reduce glucagon secretion. GLP-1 inhibitors (ex-
enatide and liraglutide) are injected 1 to 2 times a day to increase insulin secretion 
ad reduce hepatic production of sugar. Insulin sensitzers or glitazones (pioglita-
zones) are used to sensitize tissues to the effects of insulin. Rapid acting prandial 
insulin releaser “glinidit” (nateglinide,repaglinide) are consumed immediately be-
fore meal to rapidly increase the pancreas in secretion of insulin, SGLT2-I and 
acarbose. (Sydänsairudet 2014.) 
8.3.2 Drug therapy for type 2 diabetes in the USA 
Pharmacotherapy is initiated as an add-on therapy to lifestyle modification. Oral 
anti-diabetic agents / medications are initiated when starting pharmacotherapy. 
Metformin, sulphonylurea, thiazolidinedones, GLP-1 inhibitor, DPP-4 inhibitor, 
glinides, sodium glucose co-transporter 2 inhibitor (SGLT-2i), and megitimide are 
the oral anti-diabetics used in the treatment of type 2 diabetes. Most of these 
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drugs have little or no side effects. However, thiazolidinediones, sulphonylrea, 
SGLT-2i, and glinides should be used with caution. Any of these drugs could be 
used as a mono, dual and/or triple therapy, though metformin is usually the pre-
ferred first line drug to use unless contraindicated. Each therapy initiated is moni-
tored and evaluated every three months before moving on to or adding on another 
therapy or stopping some therapy. Insulin therapy is the last therapy initiated 
and/or intensified when the desired HbA1c level is not attained.  The cost and 
benefit: risk ratio is taken into consideration when choosing a medication and inef-
fective therapies are stopped. (ACCE 2013, 8.)  
8.3.3 Similarities  
Both the USA and Finland use the same or similar diagnostic criteria in diagnosing 
type2 diabetes. Upon the diagnosis of type 2 diabetes in both countries, patients 
are educated about the disease: how to deal with it or manage it with their activi-
ties of daily living and how their care plan is going to progress. The care given is 
patient centred and the goals are to: safely lower blood glucose level suing phar-
macological and non-pharmacological therapies, improve patient wellbeing, edu-
cate patients, evaluate micro and macro-vascular complications and reduce cardi-
ovascular and other possible long term risk associated with type 2 diabetes. They 
both also have similar care pathways in the treatment of type 2 diabetes, it begins 
with lifestyle modifications, with possible bariatric surgery if the patient is very 
overweight. Then initiation of pharmacotherapy, if lifestyle modification measures 
alone are not providing the desired result. The pharmacotherapy starts with oral 
anti-diabetic agent, preferably metformin and progress to insulin therapy if needed 
(Qaseem, Humphrey, Sweet, Starkey & Shekelle 2012, 221-222 ; terveykirjasto 
2015). These steps in the treatment of type 2 diabetes are known as glycaemic 
control algorithm. (IDF 2012.) 
Glycaemic control algorithm is the general treatment plan and guide used for 
type 2 diabetes and both Finland and the USA use it in the treatment guide for 
their type 2 diabetic patients. It shows the necessary steps to take when treating 
type 2 diabetes. For example, it explains what treatment to begin with and when to 
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initiate it as well as the appropriate time for next step in the treatment. Glycaemic 
control algorithm care pathway always begins with lifestyle modification interven-
tions (diet + exercise) for every type 2 diabetic patient. Oral anti-diabetic agents 
are then added to lifestyle modifications when the target level of blood glucose 
level is not achieved or maintained. The algorithm explains the kinds of possible 
medication that can be used as the first line therapy or initiating drugs, the second 
line medication therapy, the third line medication therapy, fourth line therapy as 
well as those that can be used alone (mono-therapy),  in combination with other 
agents (dual therapy) and as a triple therapy. It also explains when it is the appro-
priate time to start each therapy. Figure 5 shows an example of a typical glycae-
mic control algorithm. (ACCE  2013, 8.) 
 
Figure 6. Glycaemic control algorithm for type 2 diabetes treatment. (Medscape 
2015). 
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8.3.4 Differences 
It was found that there are no differences in the medication therapy in both Finland 
and the USA. Both countries have the same medication, such as metformin, and 
the time frame in the medication usage is also the same. 
8.4 Results outcome 
The result outcome for the treatment of type 2 diabetes showed that HbA1c level 
is reduced by 1% by all anti diabetic agents. However, metformin decreases 
HbA1c level more than DPP-4 inhibitor does. All dual or combination therapies 
were more efficient than mono-therapies and reduced HbA1c levels by an addi-
tional 1%. There was also greater decrease in HbA1c level when metformin was 
combined with other agents, for example metformin + sulphonyurea. The risk of 
hypoglycaemia is increased when increatin-based therapies are added to sulpho-
nylurae, though they are generally well tolerated and have a low risk of hy-
poglygaemia. Monotherapy with metformin resulted in more weight loss as com-
pared to thiazolidinedione, sulphonylureas and DPP-4 inhibitor. A combination 
therapy of metformin and sulphonylurea resulted in lesser weight loss as com-
pared to the combination of metformin and GLP-1 inhibitor (Qaseem, Humphrey, 
Sweet, Starkey & Shekelle 2012, 221-222.) 
To conclude, the majority of people suffering from type 2 diabetes are insulin re-
sistant or overweight. Nutritional therapy should focus on the lifestyle modifications 
to result in increased energy figure through physical activity and lowered energy 
intake. The nutritional therapy of diabetes type 2 emphasis on lifestyle planning to 
reduce glycaemia, dyslipidaemia and blood pressure; because many people with 
diabetes have hypertension and dyslipidaemia. This leads to reduction in the in-
take of cholesterol, saturated fat and sodium desirable. This planning should start 
as soon as the patient has been diagnosed with diabetes. An increase in physical 
activity can result in improved glycaemia, lowered insulin resistance, and reduced 
cardiovascular risk factors. The distribution of the food intake, three meals or 
smaller meals and snacks, should be based on individual preferences. Treatment 
with insulin therapy requires firmness in timing of meals and carbohydrate content. 
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Multiple insulin dosing regimens allow for a more flexible food intake and lifestyle 
in persons with type 2 diabetes. (American Diabetes Association 2004.) 
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9 DISCUSSION AND CONCLUSION 
9.1 Reflectiong on the review and result 
Type 2 diabetes people is widely increasing worldwide especially in united states, 
where there is lot of obesity people both adult and child. Untreated diabetes type 2 
can lead to different kind of health problem such as heart disease and stroke, 
nerve damage, kidney disease and foot problem. (NHS choices 2014).  This litera-
ture review describes the treatment both pharmacology and nutritional treatment. 
The quantity of food patient eat depend on weight, diet, exercise regularity and 
other health risk. (Medline 2013).  
In the authors experience in dealing with diabetes 2 patient in Finland hospitals, 
nurse, doctors, diabetes nurse, and dietician all work together in the process of the 
treatment. Dietician focus on diabetic patient’s food and energy intake. Patients 
are given instructions on how to count carbohydrate in their meal. Doctors and 
diabetes nurses deal with medication therapy and the usage (dosage)- Metformin, 
sulphonylurea, thiazolidinediones, GLP-1 inhibitor, DPP-4 inhibitor, glinides, sodi-
um glucose co-transporter 2 inhibitor (SGLT-2i), and megitimide. Nurses also have 
the responsibility to make sure that the carbohydrate is been counted and the doc-
tor's orders on the medication is been used. Physical activity monitoring is also 
done and encouraged by nurses and care giver need to make sure that both pa-
tient and the family member are well counselled. counselling must be on medica-
tion usage, complication if the medication is not been taken, amount of exercise 
per day, and eating habit according to the food and eating principles for type 2 di-
abetes patient. Dietician role is important when a patient is diagnosed with type 2 
diabetes, they provided tailor-made dietary plan, considering the lifestyle modifica-
tion and any medical conditions. (Theobald 2006). It was however fascinating to 
realise after the research that both Finland and USA had no difference in their care 
pathway for type 2 diabetes.  
Education needs a multidisciplinary approach, with dieticians and practice nurses 
providing evidence-based local advice to both patients and carers about nutrition 
and food, along with supporting other health-care staff to maintain an accurate and 
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consistent message. (Mellor 2012). Health professionals can help patient in plan-
ning their exercise schedule and diet intake and record their behaviour including 
challenges and positive outcome. Enough time should be taken in other for care 
givers to notice the change in social, physical, psychological factors that add to 
patient exercise and diet behaviour. Both health-care professionals and patients 
must aware that changing diet and exercise behaviour require a gradual process. 
Thus patients need to be provided with the necessary information's, motivation 
and alternative strategies during the period of weight-loss therapy so that they are 
empowered to make their own decisions (Lang and FroeUcher, 2006 as stated by 
Holt 2006). Patient who are constantly supported either by family or care givers to 
take charge in their weight loss and make lifestyle changes are likely to have an 
adequate long-term result. (Pekkarinen and Mustajoki (1997) as mentioned by Holt 
2006). 
9.1.1 Conclusion 
To conclude, it can be said that the best way to treat diabetes type 2 in both USA 
and Finland is to start with lifestyle modification, then progress to diet and medica-
tion therapy if needed.  Nurses, Doctors, Dietician, Family member as well as pa-
tient must work together to ensure good result after treatment. Patient need to be 
well counseled so they know that the treatment is a process not something they do 
and in a day and expect to be better instantly. The finding of this literature review 
shows the proper drug and diet intake for type 2 diabetes and the result include 
the treatment in USA and Finland. 
9.2 Ethical and authenticity issues 
The authors of all the articles used are mention in text (in text reference) and bibli-
ography. The thesis is literature review so it doesn’t require patient opinion or ap-
proval from health committee. No financial support or interviews needed. The re-
search is done by two student and the only background knowledge we have is 
from practical training in hospitals. Most of the articles used for this thesis were 
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from CINAHL, SAGE and some  lead us to free internet sites like America diabetes 
organization. Other articles from free internet were from trustworthy site because 
the authors had to find things specifically about USA and Finland. Website like 
Medline plus, CDC and terveyskirjasto were used.  Articles were been critically 
read through before deciding which once are important in relation to the research 
question. 
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